Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

The ability to predict drug disposition involves concurrent consideration of many chemical and physiological variables and the effect of food on the rate and extent of availability adds further complexity due to postprandial changes in the gastrointestinal (GI) tract. A system that allows for the assessment of the multivariate interplay occurring following administration of an oral dose, in the presence or absence of meal, would greatly benefit the early stages of drug development. This is particularly true in an era when the majority of new molecular entities are highly permeable, poorly soluble, extensively metabolized compounds (BDDCS Class 2), which present the most complicated relationship in defining the impact of transporters due to the marked effects of transporter-enzyme interplay. This review evaluates the GI luminal environment by taking into account the absorption/transport/elimination interplay and evaluates the physiochemical property issues by taking into account the importance of solubility, permeability and metabolism. We concentrate on the BDDCS and its utility in predicting drug disposition. Furthermore, we focus on the effect of food on the extent of drug availability (F), which appears to follow closely what might be expected if a significant effect of high fat meals is inhibition of transporters. That is, high fat meals and lipidic excipients would be expected to have little effect on F for Class 1 drugs; they would increase F of Class 2 drugs, while decreasing F for Class 3 drugs.

[1]  S. Kitagawa,et al.  Inhibition of P‐glycoprotein function by tea catechins in KB‐C2 cells , 2004, The Journal of pharmacy and pharmacology.

[2]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[3]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[4]  R. Löbenberg,et al.  Current perspectives in dissolution testing of conventional and novel dosage forms. , 2007, International journal of pharmaceutics.

[5]  R. Kim,et al.  Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides , 2005, Clinical pharmacology and therapeutics.

[6]  Y. Sugiyama,et al.  Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport , 2005, Pharmaceutical Research.

[7]  Y. Sawada,et al.  CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2005, Drug Metabolism and Disposition.

[8]  P. Welling THE EFFECTS OF FOOD ON DRUG ABSORPTION , 1996, Annual review of nutrition.

[9]  J. Tack,et al.  Parallel Monitoring of Plasma and Intraluminal Drug Concentrations in Man After Oral Administration of Fosamprenavir in the Fasted and Fed State , 2007, Pharmaceutical Research.

[10]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[11]  J. Leyden,et al.  Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. , 1985, Journal of the American Academy of Dermatology.

[12]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[13]  P. Tso,et al.  Intestinal Lipid Absorption , 2009 .

[14]  R. Kim Transporters and drug discovery: why, when, and how. , 2006, Molecular pharmaceutics.

[15]  B. Boyd,et al.  Drug Solubilization Behavior During in Vitro Digestion of Suspension Formulations of Poorly Water-Soluble Drugs in Triglyceride Lipids , 2004, Pharmaceutical Research.

[16]  P. Marathe,et al.  Development and validation of a preclinical food effect model. , 2007, Journal of pharmaceutical sciences.

[17]  Christel A. S. Bergström,et al.  In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. , 2005, Basic & clinical pharmacology & toxicology.

[18]  H vandeWaterbeemd,et al.  The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. , 1998 .

[19]  L. Benet,et al.  Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. , 2002, The Journal of pharmacology and experimental therapeutics.

[20]  P. Gershkovich,et al.  Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  S. Frokjaer,et al.  Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[23]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[24]  H. Lennernäs,et al.  The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. , 2003, British journal of clinical pharmacology.

[25]  U. Fagerholm Prediction of human pharmacokinetics —gastrointestinal absorption , 2007, The Journal of pharmacy and pharmacology.

[26]  G. Jang,et al.  Dietary Effects on Drug Metabolism and Transport , 2003, Clinical pharmacokinetics.

[27]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  Jennifer B Dressman,et al.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  Dennis A. Smith Design of drugs through a consideration of drug metabolism and pharmacokinetics , 1994, European Journal of Drug Metabolism and Pharmacokinetics.

[30]  D. Fleisher,et al.  Meal Composition Effects on the Oral Bioavailability of Indinavir in HIV-Infected Patients , 1999, Pharmaceutical Research.

[31]  R. Béliveau,et al.  Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin , 2005, Cancer Chemotherapy and Pharmacology.

[32]  Brahma N. Singh A quantitative approach to probe the dependence and correlation of food‐effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate‐release formulations , 2005 .

[33]  L. Benet,et al.  Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration , 1990, Journal of clinical pharmacology.

[34]  Y. Kashiwada,et al.  Effects of alkyl gallates on P-glycoprotein function. , 2005, Biochemical pharmacology.

[35]  W. Charman,et al.  Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .

[36]  G. Edwards,et al.  Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. , 1998, Journal of pharmaceutical sciences.

[37]  Shuzhong Zhang,et al.  Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport , 2003, Journal of Pharmacology and Experimental Therapeutics.

[38]  Y. Masaoka,et al.  Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. , 2006, Journal of pharmaceutical sciences.

[39]  Shiyin Yee,et al.  In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.

[40]  B. H. Stewart,et al.  Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes. , 1996, Journal of pharmaceutical sciences.

[41]  S. Chong,et al.  Effect of fruit juices on the oral bioavailability of fexofenadine in rats. , 2005, Journal of pharmaceutical sciences.

[42]  B. Boyd,et al.  Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. , 2005, Journal of pharmaceutical sciences.

[43]  H Lennernäs,et al.  Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models , 1997, The Journal of pharmacy and pharmacology.

[44]  R. B. Parker,et al.  Effects of Grapefruit Juice on Intestinal P‐glycoprotein: Evaluation Using Digoxin in Humans , 2003, Pharmacotherapy.

[45]  L. Benet,et al.  Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. , 2005, Molecular Pharmaceutics.

[46]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[47]  G. Amidon,et al.  Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. , 1986, Journal of pharmaceutical sciences.

[48]  J. Dressman,et al.  In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[49]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.

[50]  Kazuhiro Watanabe,et al.  Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. , 2002, Biological & pharmaceutical bulletin.

[51]  Ben J Boyd,et al.  Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. , 2004, Journal of pharmaceutical sciences.

[52]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[53]  S. Hladky,et al.  Modulatory effects of plant phenols on human multidrug‐resistance proteins 1, 4 and 5 (ABCC1, 4 and 5) , 2005, The FEBS journal.

[54]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[55]  P. Augustijns,et al.  Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. , 2003, Journal of pharmaceutical sciences.

[56]  E. D. Barnhart Physicians Desk Reference , 1990 .

[57]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[58]  Yuichi Sugiyama,et al.  Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs , 2006, Drug Metabolism and Disposition.

[59]  Wilhelm Kirch,et al.  Grapefruit Juice Ingestion Significantly Reduces Talinolol Bioavailability , 2005, Clinical pharmacology and therapeutics.

[60]  J. Spence,et al.  Ethanol enhances the hemodynamic effects of felodipine. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.

[61]  J. DeSesso,et al.  Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[62]  Lawrence X. Yu,et al.  Effect of common excipients on Caco-2 transport of low-permeability drugs. , 2001, Journal of pharmaceutical sciences.

[63]  K. Raghavan,et al.  Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties , 2007, Pharmaceutical Research.

[64]  D. Brocks,et al.  The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. , 2002, Journal of pharmaceutical sciences.

[65]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[66]  K. Wasan,et al.  Effect of Lipid Excipients on In Vitro Pancreatic Lipase Activity , 2003, Drug development and industrial pharmacy.

[67]  Kazuhiro Watanabe,et al.  Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. , 2002, Biological & pharmaceutical bulletin.

[68]  J. Dressman,et al.  Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts , 2004, The Journal of pharmacy and pharmacology.

[69]  R. Löbenberg,et al.  Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.

[70]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[71]  Michael Boyd,et al.  Potential Mechanisms by Which Peceol® Increases the Gastrointestinal Absorption of Amphotericin B , 2004, Drug development and industrial pharmacy.

[72]  Joachim Grevel,et al.  Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation , 2004, Pharmaceutical Research.

[73]  J. Kovarik,et al.  Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. , 1994, Transplantation proceedings.

[74]  J. Dressman,et al.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.

[75]  M. Morris,et al.  Effect of Organic Isothiocyanates on the P-Glycoprotein- and MRP1-Mediated Transport of Daunomycin and Vinblastine , 2002, Pharmaceutical Research.

[76]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[77]  J. Polli,et al.  Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. , 2006, Molecular pharmaceutics.

[78]  D. Fleisher,et al.  Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration , 1999, Clinical pharmacokinetics.

[79]  S. Ambudkar,et al.  Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. , 2002, Biochemical pharmacology.

[80]  Brahma N. Singh Effects of Food on Clinical Pharmacokinetics , 1999, Clinical pharmacokinetics.

[81]  Christel A. S. Bergström,et al.  Computational models to predict aqueous drug solubility, permeability and intestinal absorption , 2005, Expert opinion on drug metabolism & toxicology.

[82]  M. Ratain,et al.  The value meal: how to save $1,700 per month or more on lapatinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[84]  H. Liedholm,et al.  Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation , 1986, Clinical pharmacology and therapeutics.

[85]  J. Polli,et al.  Development of Stably Transfected Monolayer Overexpressing the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) , 2005, Pharmaceutical Research.

[86]  D. Keppler,et al.  Vectorial Transport of the Peptide CCK-8 by Double-Transfected MDCKII Cells Stably Expressing the Organic Anion Transporter OATP1B3 (OATP8) and the Export Pump ABCC2 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[87]  István Antal,et al.  In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[88]  I. Kanfer Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[89]  H. Lennernäs,et al.  A Clinical Single-Pass Perfusion Investigation of the Dynamic in Vivo Secretory Response to a Dietary Meal in Human Proximal Small Intestine , 2006, Pharmaceutical Research.

[90]  Raimar Löbenberg,et al.  Biorelevant dissolution media as a predictive tool for glyburide a class II drug. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[91]  P Augustijns,et al.  Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. , 2002, International journal of pharmaceutics.

[92]  K. Aizawa,et al.  A bitter melon extract inhibits the P‐glycoprotein activity in intestinal Caco‐2 cells: Monoglyceride as an active compound , 2004, BioFactors.

[93]  H. Lennernäs,et al.  Transport Characteristics of Fexofenadine in the Caco-2 Cell Model , 2004, Pharmaceutical Research.

[94]  J. Dressman,et al.  Characterization of the Human Upper Gastrointestinal Contents Under Conditions Simulating Bioavailability/Bioequivalence Studies , 2006, Pharmaceutical Research.

[95]  D. Small,et al.  Lipid digestion and absorption. , 1983, Annual review of physiology.

[96]  B. Schug,et al.  The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[97]  G. M. Pollack,et al.  Intestinal Absorptive Transport of the Hydrophilic Cation Ranitidine: A Kinetic Modeling Approach to Elucidate the Role of Uptake and Efflux Transporters and Paracellular vs. Transcellular Transport in Caco-2 Cells , 2006, Pharmaceutical Research.

[98]  P. Langguth,et al.  Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. , 2001, Die Pharmazie.

[99]  D. Jung,et al.  Effect of Food on the Relative Bioavailability of Oral Ganciclovir , 1996, Journal of clinical pharmacology.

[100]  J. Polli,et al.  Midazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate , 2003, Pharmaceutical Research.

[101]  G. Amidon,et al.  The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[102]  R. Löbenberg,et al.  Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[103]  U. Christians,et al.  CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam , 2004, Journal of Pharmacology and Experimental Therapeutics.

[104]  Leslie Z Benet,et al.  In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model , 2003, Journal of Pharmacology and Experimental Therapeutics.

[105]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[106]  K. Aizawa,et al.  Inhibitory effect of a bitter melon extract on the P‐glycoprotein activity in intestinal Caco‐2 cells , 2004, British journal of pharmacology.

[107]  A. Ungell,et al.  Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[108]  L. Johnson,et al.  Physiology of the gastrointestinal tract , 2012 .

[109]  Thierry Lavé,et al.  Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.

[110]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[111]  P. Artursson,et al.  Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[112]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[113]  Michael Levin Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[114]  Christel A. S. Bergström,et al.  Absorption classification of oral drugs based on molecular surface properties. , 2003, Journal of medicinal chemistry.

[115]  Patrick J. Sinko,et al.  Estimating Human Oral Fraction Dose Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-Mediated Compounds , 2004, Pharmaceutical Research.

[116]  B. Vig,et al.  Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected MDCK-hPepT1 cells to caco-2 cells , 2007, Archives of pharmacal research.

[117]  G. Dresser,et al.  The effects of fruit juices on drug disposition: a new model for drug interactions , 2003, European journal of clinical investigation.

[118]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[119]  P. Sinko,et al.  Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.

[120]  L. Benet,et al.  Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. , 2003, Current drug metabolism.

[121]  P. Gershkovich,et al.  The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. , 2007, International journal of pharmaceutics.

[122]  Y. Sawada,et al.  EFFECTS OF HERBAL EXTRACTS ON THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2006, Drug Metabolism and Disposition.